A Synergistic Approach: Enhanced Apoptotic and Proliferative Inhibition of Cisplatin by Nanocurcumin in HeLa Cells

  • Subandi Subandi Departement of Midwifery, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia https://orcid.org/0009-0002-1540-6014
  • Aura Bella Gizta Master Program of Midwifery, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia https://orcid.org/0009-0007-6157-3792
  • Fredlina Rossa Balindra Master Program of Midwifery, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia https://orcid.org/0009-0005-5706-0965
  • Kusworini Handono Departement of Clinical Pathology , Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
  • Husnul Khotimah Departement of Pharmocology, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
Keywords: cervical cancer, cisplatin, nanocurcumin, Bax, BrdU

Abstract

Cisplatin is a widely used chemotherapeutic agent for cervical cancer, but its effectiveness is often limited by cellular resistance and severe side effects. Curcumin has demonstrated potential to enhance cisplatin's anticancer effects by inducing apoptosis and inhibiting cell proliferation; however, its clinical use is constrained by poor solubility and low bioavailability. To overcome these limitations, liposomal nanocurcumin was developed. This study aimed to evaluate the synergistic effects of cisplatin and nanocurcumin on Bax and BrdU expression as markers of apoptosis and proliferation in HeLa cervical cancer cells. A true experimental post-test only design was employed with five groups: HeLa cell control (no treatment), positive control (cisplatin 5 µg/mL), and three treatment groups receiving cisplatin 2.5 µg/mL combined with nanocurcumin at 25, 50, and 100 µg/mL. Cells were incubated for 48 hours and analyzed
using flow cytometry. The combination treatment significantly increased Bax expression and reduced BrdU expression compared to cisplatin alone, with the strongest effect observed at 100 µg/mL nanocurcumin. These findings suggest that nanocurcumin may serve as a promising adjuvant to enhance the therapeutic efficacy of cisplatin by promoting apoptosis and suppressing proliferation in cervical cancer cells. 

Author Biographies

Subandi Subandi, Departement of Midwifery, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia

Departement of Midwifery, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia

Aura Bella Gizta, Master Program of Midwifery, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia

Master Program of Midwifery, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia

Fredlina Rossa Balindra, Master Program of Midwifery, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia

Master Program of Midwifery, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia

Published
2025-06-30
How to Cite
Subandi, S., Gizta, A. B., Balindra, F. R., Handono, K., & Khotimah, H. (2025). A Synergistic Approach: Enhanced Apoptotic and Proliferative Inhibition of Cisplatin by Nanocurcumin in HeLa Cells. Journal of Food and Pharmaceutical Sciences, 13(2), 122-127. https://doi.org/10.22146/jfps.21389